<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536209</url>
  </required_header>
  <id_info>
    <org_study_id>MT-8554-E03</org_study_id>
    <nct_id>NCT02536209</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacodynamic effect of single doses of
      MT-8554 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic effect as measured by Visual Analogue Scale for Cold Pressor Test</measure>
    <time_frame>up to 10 hours post dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as measured by vital signs</measure>
    <time_frame>up to Day6 of treatment period 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as measured by ECG</measure>
    <time_frame>up to Day6 of treatment period 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as measured by laboratory safety assessments</measure>
    <time_frame>up to Day6 of treatment period 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as measured by physical examination</measure>
    <time_frame>up to Day6 of treatment period 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as measured by number of participants with adverse events</measure>
    <time_frame>up to Day6 of treatment period 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of MT-8554 at the time of Pharmacodynamic assessments</measure>
    <time_frame>up to 10 hours post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Oxycodone hydrochloride at the time of Pharmacodynamic assessments</measure>
    <time_frame>up to 10 hours post dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: MT-8554 low dose, Period 2: MT-8554 high dose, Period 3: Placebo and Period 4: Oxycodone hydrochloride, respectively single dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: MT-8554 high dose, Period 2: Oxycodone hydrochloride, Period 3: MT-8554 low dose and Period 4: Placebo, respectively single dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Placebo, Period 2: MT-8554 low dose, Period 3: Oxycodone hydrochloride and Period 4: MT-8554 high dose, respectively single dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Oxycodone hydrochloride, Period 2: Placebo, Period 3: MT-8554 high dose and Period 4: MT-8554 low dose, respectively single dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-8554 low dose</intervention_name>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_label>Regimen 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-8554 high dose</intervention_name>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_label>Regimen 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone hydrochloride</intervention_name>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_label>Regimen 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_label>Regimen 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy and free from clinically significant illness or disease

          -  Male Caucasian subjects aged 18 to 55

          -  A body weight of â‰¥60 kg

        Exclusion Criteria:

          -  Participation in more than three clinical studies involving administration of an
             Investigational Medicinal Product (IMP) in the previous year, or any study within 12
             weeks.

          -  Clinically significant endocrine, thyroid, hepatic, respiratory, gastro-intestinal,
             renal, cardiovascular disease, or history of any significant psychiatric/psychotic
             illness disorder.

          -  Clinically relevant abnormal medical history, physical findings or laboratory values
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>City name</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

